Home   |   Contact   |   Phone: +49 8821 966979-0  
Meet our Managing Director & Co-Founder
Kerstin Bode-Greuel, MD, PhD
Profile
Selected Publications
Set up an appointment
Explore optimal solutions for your strategic issues
Expand all     Collapse all
Value-Driven Project & Portfolio Management
portfolio valuation methodology
portfolio management process & organization
educational in-house workshops
Financial Evaluation
individual projects (Augmented NPV)
technologies
pipeline model
Market Research & Sales Forecast
qualitative/quantitative & primary/desk market research
opinion leader/specialist interviews
conjoint analysis
overview commercial assessment
R&D & Market Risk Assessment
R&D analysis & marketing strategy
strategic risks & decision options
operational risk analysis
Licensing and M&A
potential partner identification incl. contact establishment
company valuation model creation
negotiation support
assessment of comparables
due diligence
Fund-raising
potential investor identification incl. establishment of contact
roadshow organization
negotiation support
essential documentation (information memorandum, etc.)
Bioscience Valuation in detail
www.bioscience-valuation.com
Real Options Evaluation in Pharmaceutical R&D: a new approach to financial project evaluation
SCRIP Reports, Strategic Management Series (Feb. 2000), Ref. BS1038, pages: 142

'This is a well-written report which gives great insight to the role of real options evaluation in pharmaceutical R&D. Dr. Bode-Greuel combines authority with clarity. She has very effectively reviewed the range of evaluation techniques and gives compelling reasons for the choice of approach at different stages of development'

- Dr Stephen Allport, Director, Worldwide Portfolio Planning, Glaxo Wellcome


Financial Project Evaluation and Risk Analysis in Pharmaceutial Development
SCRIP Reports, Strategic Management Series (Nov. 1997), Ref: BS890, pages: 164

'I find this report very compelling and believe the concepts presented are extremely important for the Pharma industry. The report gives a comprehensive insight into how to do financial evaluations and risk assessments of development projects and indeed a whole portfolio. It is well written and provides a clear discussion of the topic.'

- D. Stephen A. Hill, Head of Global Drug Development, Roche